No connection

Search Results

ABBV vs FMS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
FMS
Fresenius Medical Care AG
BULLISH
Price
$22.77
Market Cap
$12.44B
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
ABBV
163.63
FMS
11.56
Forward P/E
ABBV
15.42
FMS
5.62
P/B Ratio
ABBV
-146.66
FMS
0.81
P/S Ratio
ABBV
6.5
FMS
0.63
EV/EBITDA
ABBV
15.27
FMS
6.25

Profitability

Gross Margin
ABBV
71.46%
FMS
25.62%
Operating Margin
ABBV
35.5%
FMS
11.68%
Profit Margin
ABBV
4.0%
FMS
4.98%
ROE
ABBV
137.96%
FMS
7.93%
ROA
ABBV
9.59%
FMS
3.62%

Growth

Revenue Growth
ABBV
9.1%
FMS
-0.3%
Earnings Growth
ABBV
-88.7%
FMS
420.0%

Financial Health

Debt/Equity
ABBV
--
FMS
0.76
Current Ratio
ABBV
0.72
FMS
1.26
Quick Ratio
ABBV
0.47
FMS
0.85

Dividends

Dividend Yield
ABBV
3.05%
FMS
3.58%
Payout Ratio
ABBV
490.15%
FMS
42.76%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
FMS BULLISH

FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.

Strengths
Significant undervaluation relative to Graham Number and Intrinsic Value
Strong earnings recovery with YoY growth of 420%
Attractive valuation multiples (P/B 0.81, P/S 0.63, Forward P/E 5.62)
Risks
Stagnant revenue growth (-0.30% YoY) indicating a lack of top-line momentum
Severe bearish technical trend (0/100 score)
Low insider sentiment (40/100) suggesting lack of internal confidence

Compare Another Pair

ABBV vs FMS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Fresenius Medical Care AG (FMS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile